within Pharmacolibrary.Drugs.ATC.J;

model J06BD02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.2 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 15 / 1000000,
    adminCount     = 1,
    Vd             = 0.0035,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Motavizumab is a humanized monoclonal antibody that targets the fusion (F) protein of respiratory syncytial virus (RSV). It was developed for the prevention of RSV infection in high-risk infants and children; however, motavizumab is not currently approved for use due to regulatory concerns and insufficient demonstration of clinical benefit over palivizumab.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for typical healthy pediatric patients based on reported data for IgG monoclonal antibodies of similar type, as there are no peer-reviewed, published PK parameters specifically for motavizumab.</p><h4>References</h4><ol><li><p>Robbie, GJ, et al., &amp; Griffin, MP (2013). A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. <i>Antimicrobial agents and chemotherapy</i> 57(12) 6147â€“6153. DOI:<a href=&quot;https://doi.org/10.1128/AAC.01285-13&quot;>10.1128/AAC.01285-13</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24080653/&quot;>https://pubmed.ncbi.nlm.nih.gov/24080653</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J06BD02;
